Risk of harm to people with haemophilia from the 2023 WHO Essential Medicines List.

Pierce, Glenn F;O'Mahony, Brian;Kaczmarek, Radoslaw;Skinner, Mark W;World Federation of Hemophilia Coagulation Products Supply, Safety, and Access Committee (CPSSAC);et.al.
(2024) The Lancet. Haematology — Vol. 11, n° 9, p. e638-e640 (2024)

Files

2024_Pierce_Lancet_Haematol.pdf
  • Restricted Access
  • Adobe PDF
  • 207.52 KB
Request a copy

Details

Authors
  • Pierce, Glenn F
    Author
  • O'Mahony, Brian
    Author
  • Kaczmarek, Radoslaw
    Author
  • Skinner, Mark W
    Author
  • Hermans, CédricUCLouvain
    Author
  • World Federation of Hemophilia Coagulation Products Supply, Safety, and Access Committee (CPSSAC)
    Collaborator
Show more
Abstract
For 60 years, technological discoveries have greatly contributed towards changing the treatment paradigm for people with haemophilia A and B, beginning with cryoprecipitate's discovery in 1964 (see appendix p 1 for further reading). This discovery was followed by partially purified plasma-derived factor VIII and IX (FVIII and FIX, respectively) clotting factor concentrates (CFCs) as the preferred treatment by the late 1960s and early 1970s. The unintended deadly consequences of plasma pooled from up to 120 000 donors led to HIV, hepatitis B, and hepatitis C infections in thousands of people with haemophilia ( appendix p 1). [...]
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Pierce, G. F., O’Mahony, B., Kaczmarek, R., Skinner, M. W., Makris, M., Peyvandi, F., Srivastava, A., & Hermans, C. (2024). Risk of harm to people with haemophilia from the 2023 WHO Essential Medicines List. The Lancet. Haematology, 11(9), e638-e640. https://doi.org/10.1016/S2352-3026(24)00223-0 (Original work published 2024)